A role for progesterone in breast carcinogenesis is increasingly recognized. Breast cancer risk increases with the number of menstrual cycles a women experiences \[[@B1]\] and proliferation occurs in the breast epithelium during the luteal phase, when serum progesterone levels are high \[[@B2]\]. Moreover, postmenopausal women on hormone replacement therapy have increased breast cancer risk when taking combined estrogens and progestins but not with estrogens only \[[@B3]\].

Receptor activator of NF-κB ligand (RANKL) is a tumor necrosis factor (TNF) family member originally identified as a dendritic cell survival factor involved in the regulation of T-cell-dependent immune response and subsequently shown to control bone remodeling by inducing osteoclast differentiation \[[@B4]\]. Analysis of RANK- and RANKL-deficient mice pointed to a role for this pathway in the mammary gland during pregnancy \[[@B5]\] and in mammary carcinoma metastasis to the bone \[[@B6]\].

RANKL expression in the mammary epithelium is controlled by progesterone \[[@B7],[@B8]\]. Recent work identified RANKL as a key paracrine mediator of progesterone-induced mouse mammary epithelial cell proliferation \[[@B9],[@B10]\] and implicated the cytokine in stem cell control \[[@B11],[@B12]\]. Systemic inhibition of RANKL signaling by intravenous injection of recombinant osteoprotegerin, its decoy receptor, blocked progesterone-induced proliferation in the mammary epithelium, suggesting RANKL may be used as a therapeutic target in the mammary gland \[[@B9]\].

Schramek and colleagues \[[@B13]\] and Gonzalez-Suarez and colleagues \[[@B14]\] now induced mammary carcinomas in mice using the progestin medroxyprogesterone acetate (MPA) and the mutagenic agent 7,12-dimethylbenz(a) anthracene (DMBA) and demonstrate that RANKL is a key factor in this process. Over-expression of RANK by means of a mouse mammary tumor virus (MMTV)-driven transgene accelerated hyperplasia and tumor formation \[[@B14]\] whereas pharmacological inhibition of RANKL \[[@B13],[@B14]\] and genetic inactivation of RANK in the mammary epithelium \[[@B14]\] decreased incidence and delayed onset of tumorigenesis in this system.

To investigate whether RANKL is similarly important in the pathogenesis of other tumor types that arise independently of exogenous hormones, Gonzalez-Suarez and colleagues used the MMTV-neu transgenic mouse model. Interestingly, in ErbB2-driven carcinogenesis, pharmacological inhibition of RANKL also reduces tumor growth and lung metastasis, suggesting that the RANK signaling pathway may be of functional relevance in a wider tumor spectrum. This is of great clinical interest given the heterogeneity of human breast cancer. Schramek and colleagues observe that RANK deletion does not alter the incidence of mammary cancer in MMTV-neuT transgenic mice. It is conceivable that the apparent discrepancy results from Keratin5-cre RANK deleted cells being outgrown by MMTV-neuT cells that have kept the wild-type RANK allele.

Importantly, Gonzalez-Suarez and colleagues demonstrate that Fc-RANK inhibits proliferation of normal mammary epithelium and hyperplasias, but not in carcinomas, suggesting RANKL inhibition would be useful in early stages of tumorigenesis and/or as a preventive drug.

Can these findings be extrapolated to humans? Dissociation of hormone receptor expression and proliferation in the adult mammary gland is a phenomenon that is conserved between human and rodents (reviewed in \[[@B15]\]), suggesting that paracrine signals are also of relevance to the human breast. Caution is required as it is unclear whether the paracrine circuitry is shared between the two species or whether the human breast may rely on distinct factors.

Immunostainings of human breast carcinomas reveal that RANKL is expressed in 11% of human tumors. There is no evidence for colocalization within the epithelium for receptor and ligand but expression is found in some stromal cells \[[@B14]\]. This raises the possibility that the scenario is more complex in human breast cancer than in the present mouse tumor models with infiltrating immune cells providing the ligand. In any case, this drug seems too palatable not to try! The challenge lies in designing clinical trials with short endpoints and identifying adequate preclinical models to identify swiftly which particular patients may benefit from the drug.
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